Hepatitis Monthly

Published by: Kowsar

Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV

Akram Safaei 1 , Mostafa Rezaei-Tavirani 2 , ** , Afsaneh Arefi Oskouie 3 , ** , Seyed Reza Mohebbi 4 , Mahtab Shabani 5 and Afsaneh Sharifian 6
Authors Information
1 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute of Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
5 Department of Internal Medicine, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
6 Research Institute of Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: March 2017, 17 (3); e44431
  • Published Online: March 1, 2017
  • Article Type: Research Article
  • Received: December 2, 2016
  • Revised: January 8, 2017
  • Accepted: February 22, 2017
  • DOI: 10.5812/hepatmon.44431

To Cite: Safaei A, Rezaei-Tavirani M, Arefi Oskouie A, Mohebbi S R, Shabani M, et al. Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV, Hepat Mon. 2017 ;17(3):e44431. doi: 10.5812/hepatmon.44431.

Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Introduction
2. Methods
3. Results
4. Discussion
  • 1. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010; 15 Suppl 4: 14-22[DOI][PubMed]
  • 2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333-42[DOI][PubMed]
  • 3. G. B. D. Mortality , Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117-71[DOI][PubMed]
  • 4. Sorensen HT, Thulstrup AM, Mellemkjar L, Jepsen P, Christensen E, Olsen JH, et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. J Clin Epidemiol. 2003; 56(1): 88-93[PubMed]
  • 5. Hepatocellular carcinoma: management of an increasingly common problem. Baylor University Medical Center Proceedings. : 266
  • 6. Constantinou MA, Theocharis SE, Mikros E. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. Toxicol Appl Pharmacol. 2007; 218(1): 11-9[DOI][PubMed]
  • 7. Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation. 2009; 87(1): 143-52[DOI][PubMed]
  • 8. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997; 127(11): 981-5[PubMed]
  • 9. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006; 12(8): 1192-204[DOI][PubMed]
  • 10. Cequera A, Garcia de Leon Mendez MC. [Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Rev Gastroenterol Mex. 2014; 79(3): 187-99[DOI][PubMed]
  • 11. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009; 116(7): 539-64[DOI][PubMed]
  • 12. Sas KM, Karnovsky A, Michailidis G, Pennathur S. Metabolomics and diabetes: analytical and computational approaches. Diabetes. 2015; 64(3): 718-32[DOI][PubMed]
  • 13. Safaei A, Oskouie AA, Mohebbi SR, Rezaei-Tavirani M, Mahboubi M, Peyvandi M, et al. Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol Hepatol Bed Bench. 2016; 9(3): 158
  • 14. Nobakht MB, Aliannejad R, Rezaei-Tavirani M, Taheri S, Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers. 2015; 20(1): 5-16[DOI][PubMed]
  • 15. Rezaei-Tavirani M, Fathi F, Darvizeh F, Zali MR, Rostami Nejad M, Rostami K, et al. Advantage of Applying OSC to (1)H NMR-Based Metabonomic Data of Celiac Disease. Int J Endocrinol Metab. 2012; 10(3): 548-52[DOI][PubMed]
  • 16. Nobakht B, Arefi Oskouie A, Rezaei-Tavirani M, Aliannejad R, Taheri S, Fathi F, et al. NMR spectroscopy-based metabolomic study of serum in sulfur mustard exposed patients with lung disease. Biomarkers. 2016; : 1-7[DOI][PubMed]
  • 17. Corbin IR, Ryner LN, Singh H, Minuk GY. Quantitative hepatic phosphorus-31 magnetic resonance spectroscopy in compensated and decompensated cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2004; 287(2)-84[DOI][PubMed]
  • 18. Ahmad J, Downey KK, Akoad M, Cacciarelli TV. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans. Liver Transpl. 2007; 13(11): 1564-9[DOI][PubMed]
  • 19. Brown FF, Campbell ID, Kuchel PW, Rabenstein DC. Human erythrocyte metabolism studies by 1H spin echo NMR. FEBS Lett. 1977; 82(1): 12-6[PubMed]
  • 20. Viant MR. Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochem Biophys Res Commun. 2003; 310(3): 943-8[PubMed]
  • 21. Ni Y, Su M, Lin J, Wang X, Qiu Y, Zhao A, et al. Metabolic profiling reveals disorder of amino acid metabolism in four brain regions from a rat model of chronic unpredictable mild stress. FEBS Lett. 2008; 582(17): 2627-36[DOI][PubMed]
  • 22. Ayshamgul H, Batur M, Ilyar S. [1H-MRS metabonomic analysis of plasma samples of esophageal cancer patients based on different pattern recognition]. Zhonghua Zhong Liu Za Zhi. 2010; 32(9): 681-4[PubMed]
  • 23. Li S, Liu H, Jin Y, Lin S, Cai Z, Jiang Y. Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879(24): 2369-75[DOI][PubMed]
  • 24. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013; 144(5): 1066-1075 e1[DOI][PubMed]
  • 25. Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology. 2013; 58(1): 229-38[DOI][PubMed]
  • 26. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012; 15(1): 110-21[DOI][PubMed]
  • 27. Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009; 100(4): 782-5[PubMed]
  • 28. Embade N, Marino Z, Diercks T, Cano A, Lens S, Cabrera D, et al. Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. PLoS One. 2016; 11(5)[DOI][PubMed]
  • 29. Qi SW, Tu ZG, Peng WJ, Wang LX, Ou-Yang X, Cai AJ, et al. (1)H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis. World J Gastroenterol. 2012; 18(3): 285-90[DOI][PubMed]
  • 30. Kakazu E, Kondo Y, Kogure T, Ninomiya M, Kimura O, Ueno Y, et al. Plasma amino acids imbalance in cirrhotic patients disturbs the tricarboxylic acid cycle of dendritic cell. Sci Rep. 2013; 3: 3459[DOI][PubMed]
  • 31. Haussinger D, Sies H, Gerok W. Functional hepatocyte heterogeneity in ammonia metabolism. The intercellular glutamine cycle. J Hepatol. 1985; 1(1): 3-14[PubMed]
  • 32. Pratico D, Iuliano L, Basili S, Ferro D, Camastra C, Cordova C, et al. Enhanced lipid peroxidation in hepatic cirrhosis. J Investig Med. 1998; 46(2): 51-7[PubMed]
  • 33. Al Mardini H, O'Brien CJ, Bartlett K, Williams R, Record CO. Thermal desorption-gas chromatography of plasma isovaleraldehyde in hepatic encephalopathy in man. Clin Chim Acta. 1987; 165(1): 61-71[PubMed]
  • 34. Berg JM, Tymoczko JL, Stryer L. Ammonium ion is converted into urea in most terrestrial vertebrates. 2002;
  • 35. Machado MC, Pinheiro da Silva F. Hyperammonemia due to urea cycle disorders: a potentially fatal condition in the intensive care setting. J Intensive Care. 2014; 2(1): 22[DOI][PubMed]
  • 36. Maier KP, Talke H, Gerok W. Activities of urea-cycle enzymes in chronic liver disease. Klin Wochenschr. 1979; 57(13): 661-5[PubMed]
  • 37. Bugianesi E, Kalhan S, Burkett E, Marchesini G, McCullough A. Quantification of gluconeogenesis in cirrhosis: response to glucagon. Gastroenterology. 1998; 115(6): 1530-40[PubMed]
  • 38. Barbul A. Proline precursors to sustain Mammalian collagen synthesis. J Nutr. 2008; 138(10): 2021S-4S[PubMed]
  • 39. Murata K, Kudo M, Onuma F, Motoyama T. Changes of collagen types at various stages of human liver cirrhosis. Hepatogastroenterology. 1984; 31(4): 158-61[PubMed]
  • 40. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol. 1997; 27(2): 391-8[PubMed]
  • 41. Chan W, Lin S, Sun S, Liu H, Luk JM, Cai Z. Metabolomics Analysis of the Responses to Partial Hepatectomy in Hepatocellular Carcinoma Patients. Am J Analyt Chem. 2011; 2(2): 142-51[DOI]
  • 42. Yang T, Zheng X, Xing F, Zhuo H, Liu C. Serum Metabolomic Characteristics of Patients with Liver Cirrhotic Ascites. Integrat Med Int. 2015; 1(3): 136-43[DOI]
  • 43. Closs SJ. Postoperative pain at night. Nurs Times. 1991; 87(18): 40[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader